证券代码：301363 证券简称：美好医疗 公告编号：2025-042 深圳市美好创亿医疗科技股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、截至本公告披露日，深圳市美好创亿医疗科技股份有限公司（以下简称 "公司"或"本公司"）回购专用证券账户持有公司股份 1,132,048 股。根据《上 市公司股份回购规则》及《深圳证券交易所上市公司自律监管指引第 9 号——回 购股份》等相关规定，该部分已回购的股份不享有参与本次利润分配及资本公积 金转增股本的权利。因此，公司本次权益分派以现有总股本 406,660,000 股剔除 回购专用证券账户持有的 1,132,048 股后的总股本 405,527,952 股为基数，向全体 股东每 10 股派发现金红利人民币 1.00 元（含税），合计派发现金红利人民币 40,552,795.20 元（含税）；同时，以资本公积金每 10 股转增 4 股，合计转增 162,211,180 股，转增后总股本为 568,871,180 股。本次不送红股，剩余未分配利 润转结至以 ...

Core Viewpoint - Meihua Medical's stock price has experienced a slight decline, and the company has made significant adjustments to its stock incentive plans, reflecting changes in shareholder structure and performance metrics [1][2][4]. Shareholder Changes - As of May 9, 2025, the number of shareholders in Meihua Medical decreased by 525, representing a reduction of 4.85%. The average number of shares held per shareholder increased from 37,600 to 39,500, with an average holding value of 1,000,500 yuan [1][4]. Stock Incentive Plan - Meihua Medical announced the results of the first vesting period for its 2024 stock incentive plan, with 1,236,792 shares (0.30% of total shares) becoming tradable on May 16, 2025. The vesting was impacted by performance metrics, resulting in a 80% vesting ratio and the cancellation of 309,198 shares due to unfulfilled targets [1][4]. - The company held its 18th board meeting, approving the adjustment of the 2025 stock incentive plan, reducing the number of initial grantees from 304 to 303 while maintaining the total number of shares at 4,012,900. The grant date is set for May 23, 2025, with a grant price of 13.39 yuan per share [2][5]. Legal and Financial Advisory - The independent financial advisor confirmed that the adjustments and grants under the 2025 stock incentive plan comply with relevant laws and regulations, ensuring that all necessary approvals were obtained [3][5].

Core Viewpoint - The report outlines the independent financial advisory opinion regarding the 2025 Restricted Stock Incentive Plan of Shenzhen Meihua Chuangyi Medical Technology Co., Ltd, emphasizing the plan's compliance with relevant regulations and the necessary procedures for implementation [1][8]. Group 1: Incentive Plan Overview - The 2025 Restricted Stock Incentive Plan aims to motivate and retain key personnel by granting them restricted stocks, which will vest based on performance criteria [1][5]. - The plan includes a total of 500,000 shares to be granted, with specific vesting arrangements over a period of up to 54 months [4][5]. Group 2: Vesting Conditions - The vesting of the restricted stocks is contingent upon achieving certain performance targets related to revenue and net profit growth over the years 2025 to 2027 [6][7]. - The performance targets include a minimum revenue growth rate of 56.25% for 2025, 95.31% for 2026, and 144.14% for 2027, based on 2023 figures [6][7]. Group 3: Adjustments and Compliance - The plan has undergone adjustments, including the redistribution of shares from a departing incentive recipient to other eligible participants, ensuring compliance with the company's governance and regulatory requirements [3][4]. - The independent financial advisor confirms that both the company and the incentive recipients meet the necessary conditions for the grant of restricted stocks, with no disqualifying factors present [8][9].

Core Viewpoint - The legal opinion letter from Guangdong Xinda Law Firm confirms that Shenzhen Meihua Chuangyi Medical Technology Co., Ltd. has obtained the necessary approvals and fulfilled disclosure obligations for its 2025 restricted stock incentive plan adjustments and initial grants [1][10]. Group 1: Approval and Authorization - The company submitted the draft of the 2025 restricted stock incentive plan to the board for review and approval [4]. - The board approved the adjustment of the initial grant list due to one participant's resignation, reducing the number of recipients from 304 to 303 while maintaining the total stock grant of 4.0129 million shares [6][7]. Group 2: Grant Details - The grant date for the initial stock award is set for May 23, 2025, following the approval from the shareholders' meeting [6][7]. - A total of 4.0129 million shares will be granted to 303 eligible participants at a price of 13.39 yuan per share [7][9]. Group 3: Compliance with Regulations - The adjustments and grants comply with relevant laws, regulations, and the company's internal guidelines, including the Management Measures and Listing Rules [6][10]. - The company has confirmed that all grant conditions have been met, ensuring that no disqualifying circumstances exist for the participants [9][10].

Core Viewpoint - The Supervisory Board of Shenzhen Meihua Chuangyi Medical Technology Co., Ltd. has verified the list of incentive objects for the 2025 restricted stock incentive plan, confirming their eligibility and compliance with relevant regulations [1][2]. Group 1: Compliance with Regulations - The incentive objects meet the qualifications stipulated in the Company Law, Securities Law, and the company's articles of association [2]. - The incentive objects comply with the Shenzhen Stock Exchange's rules, including not being recognized as inappropriate candidates by the exchange or the China Securities Regulatory Commission (CSRC) within the last 12 months [2]. - There are no major legal violations or administrative penalties against the incentive objects in the past year, ensuring their eligibility for the incentive plan [2]. Group 2: Targeted Employees - All incentive objects are core employees of the company and its subsidiaries, excluding independent directors, aligning with the purpose of the incentive plan [2]. - The supervisory board concludes that the qualifications of the incentive objects are legal and valid [2].

证券代码：301363 证券简称：美好医疗 公告编号：2025- 039 深圳市美好创亿医疗科技股份有限公司 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届监事会 第十五次会议通知于 2025 年 5 月 20 日以书面、电话等方式送达全体监事，并于 主持，会议应到监事 3 人，实到监事 3 人，会议的召集和召开符合《中华人民共 和国公司法》《公司章程》等相关规定。 二、监事会会议审议情况 经全体与会监事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于调整 2025 年限制性股票激励计划首次授予激励对象 名单的议案》 经核查，监事会认为： 表决结果：同意 2 票；反对 0 票；弃权 0 票。关联监事邝水燕回避表决。 （二）审议通过《关于向激励对象首次授予限制性股票的议案》 经核查，监事会认为： 划的情形，公司具备实施股权激励计划的主体资格。 合《深圳证券交易所创业板股票上市规则》规定的激励对象条件，符合《2025 年 限制性股票激励计划（草案）》规定的激励 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-039 深圳市美好创亿医疗科技股份有限公司 鉴于 2025 年限制性股票激励计划（以下简称"本激励计划"）首次授予的 1 名激励对象因个人原因已离职而不得获授限制性股票，公司将前述激励对象拟 获授的限制性股票分配至首次授予的其他激励对象。调整后，首次授予的激励对 象人数由 304 人调整为 303 人，首次授予的限制性股票数量不变，仍为 401.29 万股。本次调整事项符合《上市公司股权激励管理办法》《深圳证券交易所创业 板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号—业务 办理》《2025 年限制性股票激励计划（草案）》的有关规定，同意本次调整事项。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的相关公 告。 1 第二届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届监事会 第十五次会议通知于 2025 年 5 月 20 日以书面、电 ...

法律意见书 广东信达律师事务所关于 深圳市美好创亿医疗科技股份有限公司 2025 年限制性股票激励计划调整 及首次授予事项的法律意见书 中国深圳福田区益田路 6001 号太平金融大厦 11、12 楼邮编：518038 11&12/F, TaiPing Finance Tower, 6001 Yitian Road, Futian District, Shenzhen, P.R.CHINA 电话(Tel)：(0755)88265288 传真(Fax)：(0755)88265537 电子邮件（E-mail）：info@sundiallawfirm.com 网址（Website）：https://www.sundiallawfirm.com 法律意见书 广东信达律师事务所 关于深圳市美好创亿医疗科技股份有限公司 2025 年限制性股票激励计划调整及首次授予事项的 法律意见书 信达励字（2025）058 号 致：深圳市美好创亿医疗科技股份有限公司 2 法律意见书 述时，信达已履行了必要的注意义务，但该等引述不应视为信达对这些数据、结 论的真实性和准确性作出任何明示或默示的保证。 信达在进行相关的调查、收集、查阅、查询 ...

证券代码：301363 证券简称：美好医疗 公告编号：2025-038 2025 年限制性股票激励计划（以下简称"本激励计划"）首次授予的 1 名激 励对象因个人原因已离职而不得获授限制性股票，根据《上市公司股权激励管理 办法》《深圳证券交易所创业板上市公司自律监管指南第 1 号—业务办理》《2025 年限制性股票激励计划（草案）》的有关规定，以及 2024 年年度股东大会的授 权，董事会将前述激励对象拟获授的限制性股票分配至首次授予的其他激励对 象。调整后，首次授予的激励对象人数由 304 人调整为 303 人，首次授予的限制 1 深圳市美好创亿医疗科技股份有限公司 第二届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会 第十八次会议通知于 2025 年 5 月 20 日以书面、电子邮件及电话等方式送达全体 董事，并于 2025 年 5 月 23 日在公司会议室以现场结合通讯方式召开。会议应参 加董事 9 人，实际参会董事 9 人，其中Flo ...

深圳市他山企业管理咨询有限公司 关于深圳市美好创亿医疗科技股份有限公司 2025 年限制性股票激励计划调整及首次授予事项的 独立财务顾问报告 二〇二五年五月 | 目 录 | | 2 | | --- | --- | --- | | 释 义 | | 3 | | 声 明 | | 4 | | 一、本激励计划已履行的必要程序 | | 5 | | 二、本次调整情况 | | 6 | | 三、本次授予情况 | | 7 | | 四、本次授予条件成就情况的说明 | | 11 | | 五、结论性意见 | | 12 | | 六、备查信息 | | 13 | 释 义 除非上下文文意另有所指，下列词语具有如下含义： | 美好医疗、公司 | 指 | 深圳市美好创亿医疗科技股份有限公司 | | --- | --- | --- | | 本激励计划 | 指 | 深圳市美好创亿医疗科技股份有限公司 2025 年限制性股 | | | | 票激励计划 | | 《股权激励计划（草案）》 | 指 | 《深圳市美好创亿医疗科技股份有限公司 2025 年限制性 | | | | 股票激励计划（草案）》 | | 独立财务顾问报告、本报告 | 指 | 《深圳市他山企 ...